What Is Tenax Therapeutics, Inc. (TENX) Worth in 2026?
According to the CirclFi Deep Alpha Valuation Engine, the balance of valuation evidence tilts cautious on Tenax Therapeutics, Inc. at its current price of $15.34. The composite intrinsic value is estimated at $10.69 (-30.3% average return), with 5 models flagging overvaluation risk. Notably, First Chicago sees the most upside at +41.8% (fair value: $21.75), while ML-RIV is the most conservative at -97.0% ($0.46). The spread between these extremes — +138.8% — reveals how different analytical frameworks can reach starkly different conclusions.
What Do the Models Say About TENX?
7 of 13 models are currently active for TENX. Of these, 2 models suggest upside while 5 models suggest overvaluation. The Bayesian DCF estimates TENX's intrinsic value at $6.03, implying -60.7% downside from the current price. See which stocks rank higher →
How Does TENX Rank in Pharmaceutical Preparations?
Among 431 Pharmaceutical Preparations stocks, TENX ranks #354 by Quality of Company score. CirclFi's QOC score of 3.8/10 evaluates 32 fundamental signals. A score of 3.8 signals below-average fundamentals.
See all Most Undervalued Pharmaceutical Preparations Stocks →
As a healthcare company, Tenax Therapeutics, Inc. operates in a sector where R&D productivity ratio is a critical driver of valuation. Investors evaluating TENX should weigh these sector-specific dynamics alongside our model-derived fair values.
Is TENX a Value Trap?
CirclFi's Value Trap algorithm assigns TENX a score of 27/100 (LOW). This indicates low risk. The financial profile does not exhibit typical value trap warning signs. The score cross-references apparent undervaluation against fundamental deterioration signals. Browse lowest value-trap stocks →
Multi-Model Methodology
7 of 13 models are active for Tenax Therapeutics, Inc.. Moderate coverage provides meaningful perspective. Each model applies a fundamentally different valuation philosophy. See the complete methodology →
According to the CirclFi 32-factor quality framework, Tenax Therapeutics, Inc.'s fundamental quality profile registers 3.8/10. This mixed score captures the company's profitability depth, growth consistency, balance sheet resilience, and shareholder return track record.
The gap between the most bullish and bearish model spans +138.8% — demonstrating why single-model analysis is dangerous. Browse all stocks with 13-model coverage →
Data Sources & Confidence
Every TENX valuation is built from SEC EDGAR XBRL filings — 700+ standardized financial tags. Macroeconomic context from FRED calibrates discount rates, while GDELT news sentiment feeds into our Sentiment SOTP model. All pipelines run daily. Read the complete data methodology →
Across TENX's 7 active models, average confidence is 25%. Lower confidence may reflect limited history or high volatility.
CirclFi's output is a research starting point, not a buy/sell signal. All data updates daily. Read the full methodology →
Buy with Gumroad